Literature DB >> 16104677

Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters.

Howard Cuckle1, Peter Benn, Dave Wright.   

Abstract

OBJECTIVE: To predict the screening performance for 17 policies currently in use or being considered for the near future.
METHODS: Multivariate Gaussian modeling using parameters derived from published meta-analyses and new meta-analyses for gestation-specific nuchal translucency and between trimester correlations.
RESULTS: For a 1% to 5% false-positive rate, first trimester screening achieved detection rates up to 16% to 25% higher than the best second trimester combination. Screening in both trimesters sequentially could yield an even greater increase in detection of 24% to 35%. The most efficient sequential policy was contingent screening, which has a high detection rate with only 15% of women needing second trimester tests.
CONCLUSION: Modeling with meta-analysis derived parameters provides a reliable guide for policy and favors a contingent screening policy. The widespread practice of calculating first and second trimester risks separately should be abandoned.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16104677     DOI: 10.1053/j.semperi.2005.05.004

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  9 in total

1.  Assessment of Foetal DNA in Maternal Blood - A Useful Tool in the Hands of Prenatal Specialists.

Authors:  K O Kagan; M Hoopmann; P Kozlowski
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-11       Impact factor: 2.915

Review 2.  Noninvasive prenatal testing: the future is now.

Authors:  Errol R Norwitz; Brynn Levy
Journal:  Rev Obstet Gynecol       Date:  2013

3.  Gene expression profiling in a mouse model identifies fetal liver- and placenta-derived potential biomarkers for Down Syndrome screening.

Authors:  Jeroen L A Pennings; Wendy Rodenburg; Sandra Imholz; Maria P H Koster; Conny T M van Oostrom; Timo M Breit; Peter C J I Schielen; Annemieke de Vries
Journal:  PLoS One       Date:  2011-04-14       Impact factor: 3.240

4.  Prenatal Screening Markers for Down Syndrome: Sensitivity, Specificity, Positive and Negative Expected Value Method.

Authors:  Jasmina Durković; Milan Ubavić; Milica Durković; Tibor Kis
Journal:  J Med Biochem       Date:  2018-01-01       Impact factor: 3.402

Review 5.  Association of Low Maternal Pregnancy-associated Plasma Protein A with Adverse Perinatal Outcome.

Authors:  Panagiotis Antsaklis; Zacharias Fasoulakis; Marianna Theodora; Michail Diakosavvas; Emmanuel N Kontomanolis
Journal:  Cureus       Date:  2019-06-17

Review 6.  Limitations of Aneuploidy and Anomaly Detection in the Obese Patient.

Authors:  Paula Zozzaro-Smith; Lisa M Gray; Stephen J Bacak; Loralei L Thornburg
Journal:  J Clin Med       Date:  2014-07-17       Impact factor: 4.241

7.  First Trimester Aneuploidy Screening Markers in Women with Pre-Gestational Diabetes Mellitus.

Authors:  Padmalatha Gurram; Peter Benn; James Grady; Anne-Marie Prabulos; Winston Campbell
Journal:  J Clin Med       Date:  2014-05-08       Impact factor: 4.241

Review 8.  Maternal Serum Screening Markers and Adverse Outcome: A New Perspective.

Authors:  David Krantz; Terrence Hallahan; David Janik; Jonathan Carmichael
Journal:  J Clin Med       Date:  2014-07-03       Impact factor: 4.241

9.  Analysis of Down syndrome failed to be diagnosed after prenatal screening: A multicenter study.

Authors:  Tao Jiang; Jie Ding; Xiao-Qing Zhang; Xiao-Juan Zhang; Bin Zhang; Ting Wang; Bin Yu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.